Navigation Links
Stereotaxis Reports Third Quarter Financial Results
Date:11/7/2011

ST. LOUIS, Nov. 7, 2011 /PRNewswire/ -- Stereotaxis, Inc. (NASDAQ: STXS) today reported financial results for the third quarter ended September 30, 2011.  

Third Quarter 2011 Financial ResultsRevenue for the third quarter was $8.5 million, down 38% from the year ago period.  The decrease was primarily due to softness in Niobe® robotic system sales, resulting from market demand for a more efficient solution for complex ablation procedures and the ongoing platform transition from Niobe II to the Company's new Epoch™ platform.  The Company recognized revenue on one Niobe system and $1.0 million in Odyssey™ systems in the third quarter.  Recurring revenue in the quarter was $6.5 million, a 14% increase from the year-ago quarter.  This growth was attributable to the larger installed base of Niobe systems and increased utilization leading to greater disposable sales and service contracts over last year, as well as favorable pricing.  

The Company generated global new capital orders of $2.2 million in the third quarter, which were comprised of four upgrades to the Epoch platform from Niobe II, two Vdrive™ robotic navigation systems, and $1.6 million in orders related to Odyssey.  

"Our top-line performance and system orders in the quarter, as we expected, were impacted by market demand for a more efficient solution for complex ablation procedures and the ongoing platform transition from Niobe II to Epoch," said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis.  "These factors contributed to softness in Niobe II revenue and the related impact on Odyssey installations in Niobe labs.  Meanwhile, we continue to build market momentum and interest in the Epoch platform ahead of its planned launch in December.  We remain encouraged by the early, positive market feedback
'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Stereotaxis to Report Third Quarter 2011 Financial Results and Conduct Conference Call on November 7, 2011
2. Stereotaxis to Present at the JMP Securities Healthcare Conference on September 28, 2011
3. Stereotaxis Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms
4. Stereotaxis to Present at the Stifel Nicolaus Healthcare Conference on September 7, 2011
5. Stereotaxis to Present at the Canaccord Genuity Growth Conference on August 11, 2011
6. Stereotaxis Reports Second Quarter Financial Results; Rebalances Investment Around Commercialization of Epoch™ and Odyssey™
7. Stereotaxis to Report Second Quarter 2011 Financial Results and Conduct Conference Call on August 8, 2011
8. Stereotaxis and Biosense Webster Announce New Strategic Collaboration
9. Stereotaxis Continued Leadership in Scientific Outcome Data Prominently Displayed with Multiple Key Presentations at HRS 2011
10. Stereotaxis Reports First Quarter 2011 Financial Results
11. Stereotaxis Introduces New Electrophysiology Platform: Epoch™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a ... blood purification technology to help fight deadly inflammation ... countries worldwide, today announced the appointment of Dr. ... as its Senior Vice President of Clinical Development, ... Di Russo is an accomplished pediatric ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses on ... the United States . Reimbursement analysis ... Thorough product analyses for more than 73 SMBG meters ...
(Date:12/22/2014)...  ConvaTec, a privately-held medical products and technologies company, ... Chief Executive Officer of the company, effective December 22, ... .  "The Board of Directors of ConvaTec thanks Mr. ... past three years," said Magnus Lundberg , the ... that the company is well positioned for the future."  ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... ADDISON, Texas, Oct. 13, 2011 ULURU Inc. (NYSE ... a binding letter of intent with Melmed Holdings AG, a company ... Under the terms of the agreement ULURU will license the ... formed to market Altrazeal® in the European Union. In exchange for ...
... Clean Holdings, Inc. (Nasdaq: UCTT ), a leading ... equipment, flat panel, medical, energy and research industries will release ... 24, 2011 after markets close. The Company will ... and management,s outlook at 1:45 pm PDT on Monday, October ...
Cached Medicine Technology:ULURU Inc. Announces Altrazeal® Agreement for the European Market 2ULURU Inc. Announces Altrazeal® Agreement for the European Market 3
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
(Date:12/25/2014)... Plugin creators from Pixel Film Studios ... customizable business presentation tool made specifically for Final ... business tool, users can now display their stats and ... Film Studios. “ProFire 5k gives users a multiple options ... to a presentation” , Pixel Film Studios takes the ...
(Date:12/25/2014)... Each year trauma accounts for approximately ... admissions across the nation (according to the Centers ... National Hospital Ambulatory Medical Care Survey collected data ... 2010. They estimated that there were between 3.5 and ... primary diagnosis of broken bone or fracture. , ...
(Date:12/24/2014)... Wauwatosa, Wi (PRWEB) December 25, 2014 ... who are unable to afford certain items. During the holiday ... , "We collected over 70 toys," says Dr. Sara Mahalko-Leonhardt, ... myself and staff such joy, knowing that we are able ... any present had it not been for the generosity of ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) a specialty pharmaceutical ... that they anticipate reporting top-line results from their current ... of 2009. , , The Phase ... trial to evaluate the efficacy and safety of Ketotransdel, ...
... High Resolution Monitoring of Drug Efficacy and Safety ... Based on its recent analysis in the ... & Sullivan recognizes Singulex, Inc. with the 2009 ... Innovation for pioneering the Erenna Immunoassay System. This ...
... NTY ) ( www.NBTY.com ), a leading global manufacturer and marketer of nutritional supplements, today announced the ... unaudited net sales results for May 2009 by segment are as follows: , , , ... NET SALES, ... (Preliminary and Unaudited), ...
... -- As the slumping economy continues to ... streamlining costs and creating additional efficiencies while continuing to ... those in need for charity care or self-pay discounts. ... landscape, TransUnion announced today new enhancements to its patented ...
... ... seniors nationwide. , ... (Vocus) June 15, 2009 -- VaxAmerica, a program of FFF Enterprises, Inc., ... into a partnership with Emeritus Senior Living. The alliance will encourage the 26,500 seniors ...
... ... have developed the strongest and most effective libido/intimacy enhancement therapy called VaietTM 110/L-Arginine for ... ... to announce the release of their exclusive Viagra/Arginine Intimacy Enhancement Therapy or VAIET (named ...
Cached Medicine News:Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 2Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 3Health News:Frost & Sullivan Recognizes Singulex for Erenna(R) Immunoassay System 2Health News:Frost & Sullivan Recognizes Singulex for Erenna(R) Immunoassay System 3Health News:Frost & Sullivan Recognizes Singulex for Erenna(R) Immunoassay System 4Health News:NBTY Announces Preliminary Unaudited Net Sales Results for May 2009 2Health News:NBTY Announces Preliminary Unaudited Net Sales Results for May 2009 3Health News:NBTY Announces Preliminary Unaudited Net Sales Results for May 2009 4Health News:TransUnion Revenue Manager(SM) Meets Healthcare Challenges Brought On By Today's Economy with New Features 2Health News:TransUnion Revenue Manager(SM) Meets Healthcare Challenges Brought On By Today's Economy with New Features 3Health News:VaxAmerica Enters Partnership with Emeritus Senior Living 2Health News:VaxAmerica Enters Partnership with Emeritus Senior Living 3Health News:After 10 Years A Stronger and More Enhanced Form of Viagra Now Available 2Health News:After 10 Years A Stronger and More Enhanced Form of Viagra Now Available 3Health News:After 10 Years A Stronger and More Enhanced Form of Viagra Now Available 4
Indications For Usage: , Thoracic surgery. , Broncho-spirometry. , Thoracoscopies. , Differential or selective lung ventilation. ...
... Double lumen ... one-lung ventilation., ... Tube is packaged ... tube-to-circuit adaptors, suction ...
The TCB Univent® allows easily collapsing one lung for thoracoscopic procedures....
... Used for endobronchial blockade ... right lung for procedures ... The set consists of ... and an Arndt Multiport ...
Medicine Products: